UnitedHealth Group, Eli Lilly and Company, Insmed, Johnson & Johnson, Moderna, Merck & Co., Inc., and AbbVie are the seven Healthcare stocks to watch today, according to MarketBeat's stock screener tool. Healthcare stocks are shares of companies involved in healthcare, such as pharmaceutical and biotechnology firms, medical-device makers, hospitals, and health insurers. For investors, their performance can depend on factors including medical innovation, regulation, clinical-trial results, and demand for healthcare services. These companies had the highest dollar trading volume of any Healthcare stocks within the last several days.
UnitedHealth Group (UNH)
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.
Shares of UnitedHealth Group stock traded down $18.16 during trading on Thursday, reaching $331.75. 10,922,027 shares of the stock traded hands, compared to its average volume of 7,219,043. UnitedHealth Group has a 52-week low of $255.96 and a 52-week high of $461.62. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.74 and a quick ratio of 0.74. The business has a fifty day simple moving average of $390.56 and a two-hundred day simple moving average of $367.04. The company has a market capitalization of $297.25 billion, a price-to-earnings ratio of 18.95, a P/E/G ratio of 1.41 and a beta of 0.51.
Read Our Latest Research Report on UNH
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Eli Lilly and Company stock traded down $26.60 during midday trading on Thursday, reaching $1,356.15. 1,492,783 shares of the stock traded hands, compared to its average volume of 2,950,260. The stock has a market cap of $1.28 trillion, a P/E ratio of 44.02, a PEG ratio of 1.69 and a beta of 0.40. The stock's fifty day moving average is $1,258.86 and its 200-day moving average is $1,115.99. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17. Eli Lilly and Company has a 12 month low of $850.51 and a 12 month high of $1,475.25.
Read Our Latest Research Report on LLY
Insmed (INSM)
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
Shares of INSM traded up $22.21 during mid-day trading on Thursday, hitting $142.01. 9,738,233 shares of the stock were exchanged, compared to its average volume of 3,023,725. The company has a market cap of $31.16 billion, a PE ratio of -50.58 and a beta of 0.83. Insmed has a 52-week low of $90.39 and a 52-week high of $212.75. The firm has a 50-day moving average of $110.51 and a two-hundred day moving average of $122.84. The company has a debt-to-equity ratio of 0.77, a quick ratio of 2.59 and a current ratio of 2.86.
Read Our Latest Research Report on INSM
Johnson & Johnson (JNJ)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Shares of JNJ stock traded down $5.97 on Thursday, reaching $266.73. The company's stock had a trading volume of 4,317,400 shares, compared to its average volume of 7,939,087. The stock's fifty day simple moving average is $267.42 and its 200-day simple moving average is $250.61. Johnson & Johnson has a 1 year low of $199.90 and a 1 year high of $290.25. The company has a market capitalization of $642.11 billion, a price-to-earnings ratio of 40.44, a price-to-earnings-growth ratio of 2.75 and a beta of 0.22. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44.
Read Our Latest Research Report on JNJ
Moderna (MRNA)
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
MRNA stock traded up $5.76 during trading on Thursday, hitting $202.55. 4,965,753 shares of the company's stock traded hands, compared to its average volume of 12,466,779. Moderna has a 52 week low of $22.28 and a 52 week high of $280.80. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.47 and a current ratio of 3.62. The business has a fifty day simple moving average of $205.61 and a 200 day simple moving average of $98.82. The stock has a market capitalization of $81.95 billion, a price-to-earnings ratio of -28.70 and a beta of 1.16.
Read Our Latest Research Report on MRNA
Merck & Co., Inc. (MRK)
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
MRK traded down $4.46 during trading on Thursday, reaching $133.32. The company had a trading volume of 5,233,512 shares, compared to its average volume of 10,501,186. The company has a quick ratio of 1.14, a current ratio of 1.35 and a debt-to-equity ratio of 1.11. The business has a 50 day simple moving average of $145.73 and a 200-day simple moving average of $129.11. The stock has a market cap of $328.67 billion, a P/E ratio of 137.71, a PEG ratio of 6.57 and a beta of 0.13. Merck & Co., Inc. has a 52 week low of $93.90 and a 52 week high of $156.92.
Read Our Latest Research Report on MRK
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
ABBV stock traded down $2.91 during mid-day trading on Thursday, reaching $283.10. 2,042,783 shares of the stock traded hands, compared to its average volume of 6,258,335. AbbVie has a one year low of $190.75 and a one year high of $302.93. The stock has a market capitalization of $500.41 billion, a PE ratio of 48.77, a PEG ratio of 1.33 and a beta of 0.20. The business has a 50-day moving average price of $277.84 and a two-hundred day moving average price of $241.96.
Read Our Latest Research Report on ABBV
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider UnitedHealth Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UnitedHealth Group wasn't on the list.
While UnitedHealth Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.